Logo

Takeda's Entyvio (vedolizumab) Receives NMPA's Approval to Treat Moderate to Severe Active Ulcerative Colitis and Crohn's Disease

Share this

Takeda's Entyvio (vedolizumab) Receives NMPA's Approval to Treat Moderate to Severe Active Ulcerative Colitis and Crohn's Disease

Shots:

  • The NMPA has approved Entyvio to treat patients with moderately to severely active UC & CD having inadequate response to- lost response to- or were intolerant to conventional therapies or TNFα inhibitors
  • In 2018- NMPA has included the therapy in the first batch list of ‘urgently needed’ overseas medicines for accelerated approval
  • Entyvio (IV) is a gut-selective mAb- designed to specifically antagonize the α4β7 integrin to intestinal (MAdCAM-1) but not VCAM-1 and has received marketing authorization in 60+ countries including the US and EU

Click here to­ read full press release/ article 

 Ref: Takeda | Image:Takeda


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions